Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13628)	9/21/2004 2:31:33 PM
From: SofaSpud	Respond to of 14101

Dimethaid shareholders elect new board of directors TORONTO, Sept. 21 /CNW/ - Shareholders of Dimethaid Research Inc. (TSX: DMX) elected a new board of directors at today's Annual General Meeting. The new board consists of Daniel H. Chicoine, David A. Copeland, Anthony E. Dobranowski, Dr. Henrich R.K. Guntermann, Dr. Klaus von Lindeiner, John C. London and Dr. Jacques Messier. The Company's auditors Schwartz, Levitsky and Feldman were reappointed until the next annual meeting of shareholders. About Dimethaid Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Québec and Wanzleben, Germany. The company develops and commercializes targeted therapeutic drugs designed to produce minimal side effects. Dimethaid's two technology platforms focus on transcellular drug delivery and immune system regulation. Products are aimed at expanding treatment options in rheumatology, dermatology, oncology, immunology, and the therapeutic management of chronic viral infections. For more information, please visit www.dimethaid.com. This release may contain forward-looking statements, subject to risks and uncertainties beyond management's control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Company's annual information form filed with the securities commissions in each of the provinces of Canada. The Company undertakes no obligation to revise forward-looking statements in light of future events.